360 related articles for article (PubMed ID: 34515902)
21. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
Mease PJ; Chohan S; Fructuoso FJG; Luggen ME; Rahman P; Raychaudhuri SP; Chou RC; Mendelsohn AM; Rozzo SJ; Gottlieb A
Ann Rheum Dis; 2021 Sep; 80(9):1147-1157. PubMed ID: 33985942
[TBL] [Abstract][Full Text] [Related]
22. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
Coates LC; Gossec L; Zimmermann M; Shawi M; Rampakakis E; Shiff NJ; Kollmeier AP; Xu XL; Nash P; Mease PJ; Helliwell PS
RMD Open; 2024 Mar; 10(1):. PubMed ID: 38531621
[TBL] [Abstract][Full Text] [Related]
23. Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.
Pham PA; Dressler C; Eisert L; Nast A; Werner RN
Rheumatol Int; 2019 Apr; 39(4):605-618. PubMed ID: 30684041
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of adalimumab in Japanese patients with psoriatic arthritis and inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs): A prospective, observational study.
Morita A; Okuyama R; Katoh N; Tateishi C; Masuda K; Komori T; Ogawa E; Makino T; Nishida E; Nishimoto S; Muramoto K; Tsuruta D; Ihn H
Mod Rheumatol; 2020 Jan; 30(1):155-165. PubMed ID: 30836036
[No Abstract] [Full Text] [Related]
25. Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
Arthritis Rheumatol; 2017 Nov; 69(11):2151-2161. PubMed ID: 28805045
[TBL] [Abstract][Full Text] [Related]
26. Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study.
Coates LC; Helliwell PS
J Rheumatol; 2016 Feb; 43(2):356-61. PubMed ID: 26669913
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Chakravarty SD; Xu XL; Subramanian RA; Agarwal P; Sheng S; Jiang Y; Zhou B; Zhuang Y; van der Heijde D; Mease PJ
Arthritis Rheumatol; 2021 Apr; 73(4):604-616. PubMed ID: 33043600
[TBL] [Abstract][Full Text] [Related]
28. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
[TBL] [Abstract][Full Text] [Related]
30. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
Mease PJ; Ory P; Sharp JT; Ritchlin CT; Van den Bosch F; Wellborne F; Birbara C; Thomson GT; Perdok RJ; Medich J; Wong RL; Gladman DD
Ann Rheum Dis; 2009 May; 68(5):702-9. PubMed ID: 18684743
[TBL] [Abstract][Full Text] [Related]
31. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
Mease PJ; Gladman DD; Deodhar A; McGonagle DG; Nash P; Boehncke WH; Gottlieb A; Xu XL; Xu S; Hsia EC; Karyekar CS; Helliwell PS
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665433
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
[TBL] [Abstract][Full Text] [Related]
33. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.
Gladman DD; Orbai AM; Klitz U; Wei JC; Gallo G; Birt J; Rathmann S; Shrom D; Marzo-Ortega H
Arthritis Res Ther; 2019 Jan; 21(1):38. PubMed ID: 30696483
[TBL] [Abstract][Full Text] [Related]
34. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review.
Xie Y; Liu Y
Clin Exp Dermatol; 2022 Sep; 47(9):1627-1635. PubMed ID: 35466472
[TBL] [Abstract][Full Text] [Related]
35. Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials.
Tillett W; Lin CY; Trevelin Sprabery A; Birt JA; Kavanaugh A
Clin Exp Rheumatol; 2020; 38(6):1227-1230. PubMed ID: 32452352
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.
Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Lu W; Wang Z; Soliman AM; Eldred A; Barcomb L; Behrens F
Ann Rheum Dis; 2022 Feb; 81(2):225-231. PubMed ID: 34911706
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.
Mease P; Helliwell P; Silwinska-Stanczyk P; Miakisz M; Ostor A; Peeva E; Vincent MS; Sun Q; Sikirica V; Winnette R; Qiu R; Li G; Feng G; Beebe JS; Martin DA
Arthritis Rheumatol; 2023 Aug; 75(8):1370-1380. PubMed ID: 37194394
[TBL] [Abstract][Full Text] [Related]
39. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).
Antoni CE; Kavanaugh A; van der Heijde D; Beutler A; Keenan G; Zhou B; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman DD; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen JS
J Rheumatol; 2008 May; 35(5):869-76. PubMed ID: 18381786
[TBL] [Abstract][Full Text] [Related]
40. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).
Gottlieb AB; Strand V; Kishimoto M; Mease P; Thaçi D; Birt J; Lee CH; Shuler CL; Lin CY; Gladman DD
Rheumatology (Oxford); 2018 Oct; 57(10):1777-1788. PubMed ID: 29945203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]